NCT04463004View on ClinicalTrials.gov

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
COVID-19Sars-CoV2Pneumonia
Interventions
DRUG

Mavrilimumab

Treatment infusion

DRUG

Placebos

Placebo infusion

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

Sponsors
All Listed Sponsors
collaborator

Kiniksa Pharmaceuticals, Ltd.

INDUSTRY

lead

Virginia Commonwealth University

OTHER

NCT04463004 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Biotech Hunter | Biotech Hunter